High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

Anna Jamnitski; Johannes H. Levels; Inge A. van den Oever; Michael T. Nurmohamed

doi:https://doi.org/10.3899/jrheum.121358

High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

Anna Jamnitski, Johannes H. Levels, Inge A. van den Oever, Michael T. Nurmohamed

Research output: Contribution to journal › Article › Academic › peer-review

27 Citations (Scopus)

Abstract

Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response. Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months' therapy. There were no significant differences in HDL profiling in EULAR nonresponders. Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition

Original language	English
Pages (from-to)	825-830
Journal	Journal of rheumatology
Volume	40
Issue number	6
DOIs	https://doi.org/10.3899/jrheum.121358
Publication status	Published - 2013

Access to Document

https://doi.org/10.3899/jrheum.121358

Cite this

@article{c8c6d99069534434a2cc993f091893f6,

title = "High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study",

abstract = "Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response. Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months' therapy. There were no significant differences in HDL profiling in EULAR nonresponders. Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition",

author = "Anna Jamnitski and Levels, {Johannes H.} and {van den Oever}, {Inge A.} and Nurmohamed, {Michael T.}",

year = "2013",

doi = "https://doi.org/10.3899/jrheum.121358",

language = "English",

volume = "40",

pages = "825--830",

journal = "Journal of rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "6",

}

TY - JOUR

T1 - High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

AU - Jamnitski, Anna

AU - Levels, Johannes H.

AU - van den Oever, Inge A.

AU - Nurmohamed, Michael T.

PY - 2013

Y1 - 2013

N2 - Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response. Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months' therapy. There were no significant differences in HDL profiling in EULAR nonresponders. Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition

AB - Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response. Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months' therapy. There were no significant differences in HDL profiling in EULAR nonresponders. Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition

U2 - https://doi.org/10.3899/jrheum.121358

DO - https://doi.org/10.3899/jrheum.121358

M3 - Article

C2 - 23637327

SN - 0315-162X

VL - 40

SP - 825

EP - 830

JO - Journal of rheumatology

JF - Journal of rheumatology

IS - 6

ER -